Reumatologia

EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis.

Annals of the rheumatic diseases. 2025 Oct; doi: 10.1016/j.ard.2025.10.002. pii: S0003-4967(25)04433-4.

EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update.

Annals of the rheumatic diseases. 2025 Oct; doi: 10.1016/j.ard.2025.09.007. pii: S0003-4967(25)04412-7.

The concept of severity in psoriatic arthritis: a scoping review of the literature.

Journal of autoimmunity. 2025 Dec; 157(Dec):103494. doi: 10.1016/j.jaut.2025.103494. pii: S0896-8411(25)00139-8.

Osteoarthritis year in review 2025: Imaging.

Osteoarthritis and cartilage. 2025 Nov; doi: 10.1016/j.joca.2025.11.004. pii: S1063-4584(25)01226-9.

2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis.

Arthritis & rheumatology (Hoboken, N.J.). 2025 Sep; 77(Sep):1115-1135. doi: 10.1002/art.43212. pii: .

Assessment of triple antiphospholipid antibody-positive patients based on clinical and laboratory domains of 2023 ACR/EULAR antiphospholipid syndrome classification criteria.

Seminars in arthritis and rheumatism. 2025 Oct; 74(Oct):152768. doi: 10.1016/j.semarthrit.2025.152768. pii: S0049-0172(25)00139-8.

Parathyroid hormone receptor agonists in the management of osteoporosis.

Nature reviews. Rheumatology. 2025 Oct; 21(Oct):599-611. doi: 10.1038/s41584-025-01287-w. pii: .

Advancing Juvenile Spondyloarthritis: Closing Knowledge Gaps with New Axial JSpA Classification Criteria.

Current rheumatology reports. 2025 Nov; 27(Nov):39. doi: 10.1007/s11926-025-01206-8. pii: 39.

Vaccination Update and Specific Concerns for RA.

Current rheumatology reports. 2025 Sep; 27(Sep):37. doi: 10.1007/s11926-025-01197-6. pii: 37.

Behçet's syndrome: one year in review 2025.

Clinical and experimental rheumatology. 2025 Oct; 43(Oct):1699-1708. doi: 10.55563/clinexprheumatol/8xuim0. pii: .

Efficacy and Safety of Zimlovisertib, Ritlecitinib, and Tofacitinib, Alone and in Combination, in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate.

Arthritis & rheumatology (Hoboken, N.J.). 2025 Oct; 77(Oct):1337-1348. doi: 10.1002/art.43184. pii: .

Expert Perspective: How, When, and Why to Potentially Stop Antiresorptive Drugs in Osteoporosis.

Arthritis & rheumatology (Hoboken, N.J.). 2025 Oct; 77(Oct):1294-1304. doi: 10.1002/art.43179. pii: .

Investigating endogenous immune-mediated monocyte memory in rheumatoid arthritis.

Annals of the rheumatic diseases. 2025 Sep; 84(Sep):1484-1500. doi: 10.1016/j.ard.2025.03.016. pii: S0003-4967(25)00883-0.

Rapid radiographic progression in rheumatoid arthritis: Definition, prediction and treatment.

Autoimmunity reviews. 2025 Sep; 24(Sep):103913. doi: 10.1016/j.autrev.2025.103913. pii: S1568-9972(25)00174-0.

Current Challenges and Emerging Therapies in the Treatment of Gout.

Current rheumatology reviews. 2025 ; 21():239-251. doi: 10.2174/0115733971302054240627072809. pii: .

Dynamic macrophage phenotypes in autoimmune and inflammatory rheumatic diseases.

Nature reviews. Rheumatology. 2025 Sep; 21(Sep):546-565. doi: 10.1038/s41584-025-01279-w. pii: .

Integrating handheld ultrasound in rheumatology: A review of benefits and drawbacks.

Best practice & research. Clinical rheumatology. 2025 Sep; 39(Sep):102085. doi: 10.1016/j.berh.2025.102085. pii: S1521-6942(25)00053-1.

Imaging for inflammatory neuropathies.

Best practice & research. Clinical rheumatology. 2025 Sep; 39(Sep):102066. doi: 10.1016/j.berh.2025.102066. pii: S1521-6942(25)00034-8.

Imaging in sarcoid disease.

Best practice & research. Clinical rheumatology. 2025 Sep; 39(Sep):102054. doi: 10.1016/j.berh.2025.102054. pii: S1521-6942(25)00022-1.

Imaging of crystal-induced arthropathies in 2025.

Best practice & research. Clinical rheumatology. 2025 Sep; 39(Sep):102063. doi: 10.1016/j.berh.2025.102063. pii: S1521-6942(25)00031-2.

Pathogenesis of juvenile idiopathic arthritis.

Current opinion in rheumatology. 2025 Sep; 37(Sep):321-326. doi: 10.1097/BOR.0000000000001099. pii: .

The 2025 British Society for Rheumatology management recommendations for ANCA-associated vasculitis.

Rheumatology (Oxford, England). 2025 Aug; 64(Aug):4470-4494. doi: 10.1093/rheumatology/keaf240. pii: .

Treatment of interstitial lung disease in systemic sclerosis: guidelines and new clinical trial results.

Current opinion in rheumatology. 2024 Nov; 36(Nov):420-426. doi: 10.1097/BOR.0000000000001049. pii: .

ERN ReCONNET-SLICC-SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations.

The Lancet. Rheumatology. 2025 May; doi: 10.1016/S2665-9913(25)00063-3. pii: S2665-9913(25)00063-3.

2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.

Arthritis & rheumatology (Hoboken, N.J.). 2024 Aug; 76(Aug):1201-1213. doi: 10.1002/art.42860. pii: .

2023 International Rome consensus for the nomenclature of Sjögren disease.

Nature reviews. Rheumatology. 2025 Jun; doi: 10.1038/s41584-025-01268-z. pii: .

Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update.

Annals of the rheumatic diseases. 2025 May; 84(May):664-679. doi: 10.1016/j.ard.2025.01.032. pii: S0003-4967(25)00181-5.

The Assessment of SpondyloArthritis International Society (ASAS) Consensus-Based Expert Definition of Difficult-to-Manage, including Treatment-Refractory, Axial Spondyloarthritis.

Annals of the rheumatic diseases. 2025 Apr; 84(Apr):538-546. doi: 10.1016/j.ard.2025.01.035. pii: S0003-4967(25)00185-2.

Position statement on infection screening, prophylaxis, and vaccination of pediatric patients with rheumatic diseases and immunosuppressive therapies, part 3: precautions in situations of surgery, fever, and opportunistic infections.

European journal of pediatrics. 2024 Feb; 183(Feb):915-927. doi: 10.1007/s00431-023-05295-4. pii: .

The British Society for Rheumatology guideline for the management of foot health in inflammatory arthritis.

Rheumatology (Oxford, England). 2025 May; 64(May):2355-2368. doi: 10.1093/rheumatology/keaf071. pii: .

European expert recommendations for managing systemic sclerosis and its complications.

Nature reviews. Rheumatology. 2025 Mar; 21(Mar):133-134. doi: 10.1038/s41584-024-01205-6. pii: .

Brazilian recommendations for the management of tuberculosis infection in immune-mediated inflammatory diseases.

Advances in rheumatology (London, England). 2025 Mar; 65(Mar):18. doi: 10.1186/s42358-025-00449-4. pii: .

International Consensus Guidance for the Management of Glucocorticoid Related Complications in Neuromuscular Disease.

Muscle & nerve. 2025 Mar; 71(Mar):309-316. doi: 10.1002/mus.28328. pii: .

Pediatric Society of the African League Against Rheumatism juvenile idiopathic arthritis recommendations for enthesitis-related arthritis and juvenile psoriatic arthritis.

Clinical rheumatology. 2025 Mar; 44(Mar):901-922. doi: 10.1007/s10067-025-07334-x. pii: .

Enhancing current guidance for psoriatic arthritis and its comorbidities: recommendations from an expert consensus panel.

Rheumatology (Oxford, England). 2025 Feb; 64(Feb):561-573. doi: 10.1093/rheumatology/keae172. pii: .

British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.

Rheumatology (Oxford, England). 2025 Feb; 64(Feb):409-439. doi: 10.1093/rheumatology/keae152. pii: .

The 2024 British Society for Rheumatology guideline for management of systemic sclerosis.

Rheumatology (Oxford, England). 2024 Nov; 63(Nov):2956-2975. doi: 10.1093/rheumatology/keae394. pii: .

The 2024 APLAR Consensus on the Management of Lupus Nephritis.

International journal of rheumatic diseases. 2025 Jan; 28(Jan):e70021. doi: 10.1111/1756-185X.70021. pii: .

British Association of Dermatologists and British Society for Rheumatology living guideline for managing people with Behçets 2024.

Rheumatology (Oxford, England). 2025 Jan; 64(Jan):74-90. doi: 10.1093/rheumatology/keae438. pii: .

Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement.

JAMA. 2025 Feb; 333(Feb):498-508. doi: 10.1001/jama.2024.27154. pii: .

2022 American College of Rheumatology Guideline for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis.

Arthritis care & research. 2023 Aug; 75(Aug):1603-1615. doi: 10.1002/acr.25117. pii: .

Expert consensus recommendations for the diagnosis and treatment of chronic non-bacterial osteitis (CNO) in adults.

Annals of the rheumatic diseases. 2024 Nov; doi: 10.1136/ard-2024-226446. pii: ard-2024-226446.

Global RA treatment recommendations: An update from the various international societies.

Best practice & research. Clinical rheumatology. 2024 Nov; 102019. doi: 10.1016/j.berh.2024.102019. pii: S1521-6942(24)00090-1.

Disease activity score for still's disease.

Clinical rheumatology. 2024 Nov; 43(Nov):3273-3283. doi: 10.1007/s10067-024-07127-8. pii: .

Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's disease.

Annals of the rheumatic diseases. 2024 Nov; 83(Nov):1731-1747. doi: 10.1136/ard-2024-225854. pii: .

The 2024 British Society for Rheumatology guideline for management of systemic sclerosis-executive summary.

Rheumatology (Oxford, England). 2024 Nov; 63(Nov):2948-2955. doi: 10.1093/rheumatology/keae390. pii: .

The concept of severity in psoriatic arthritis: a scoping review of the literature.

Journal of autoimmunity. 2025 Dec; 157(Dec):103494. doi: 10.1016/j.jaut.2025.103494. pii: S0896-8411(25)00139-8.

Personalized Medicine for Systemic Sclerosis-Associated Interstitial Lung Disease.

Current treatment options in rheumatology. 2025 Dec; 11(Dec):doi: 10.1007/s40674-024-00221-7. pii: 2.

Advancing Juvenile Spondyloarthritis: Closing Knowledge Gaps with New Axial JSpA Classification Criteria.

Current rheumatology reports. 2025 Nov; 27(Nov):39. doi: 10.1007/s11926-025-01206-8. pii: 39.

Osteoarthritis year in review 2025: Imaging.

Osteoarthritis and cartilage. 2025 Nov; doi: 10.1016/j.joca.2025.11.004. pii: S1063-4584(25)01226-9.

Validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) in Brazilian SLE patients.

Rheumatology (Oxford, England). 2025 Nov; 64(Nov):5811-5817. doi: 10.1093/rheumatology/keaf366. pii: .

New 2025 British Society for Rheumatology (BSR) management recommendations for ANCA-associated vasculitis: what each new guideline tells us and why we should read them all.

Rheumatology (Oxford, England). 2025 Nov; 64(Nov):5585-5588. doi: 10.1093/rheumatology/keaf452. pii: .

EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis.

Annals of the rheumatic diseases. 2025 Oct; doi: 10.1016/j.ard.2025.10.002. pii: S0003-4967(25)04433-4.

EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update.

Annals of the rheumatic diseases. 2025 Oct; doi: 10.1016/j.ard.2025.09.007. pii: S0003-4967(25)04412-7.

Skin Deep: A Narrative Case Series and Review of Cutaneous Vasculitis and Possible Doppelgängers.

The American journal of medicine. 2025 Oct; 138(Oct):1352-1359. doi: 10.1016/j.amjmed.2025.05.043. pii: S0002-9343(25)00351-1.

Expert Perspective: How, When, and Why to Potentially Stop Antiresorptive Drugs in Osteoporosis.

Arthritis & rheumatology (Hoboken, N.J.). 2025 Oct; 77(Oct):1294-1304. doi: 10.1002/art.43179. pii: .